CD279 Mouse anti-Human, PE-CF594, Clone: EH12.1, BD
Mouse Monoclonal Antibody
Manufacturer: BD Biosciences 565024
The EH12.1 monoclonal antibody specifically binds to CD279. CD279 is an immunoregulatory receptor that is expressed on activated T cells, B cells and myeloid cells and contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region. Mice deficient in CD279 show a breakdown of peripheral tolerance and manifest multiple autoimmune symptoms. PD-L1 and PD-L2 are ligands of CD279 and are members of the B7 gene family. Interaction of CD279:PD-Ligands results in inhibition of T cell proliferation and cytokine secretion. Reports suggest that the B7/CTLA-4 pathway functions primarily to attenuate, limit, and/or terminate naοve T-cell activation in secondary lymphoid organs. The PD-ligand:CD279 pathway, on the other hand, may primarily attenuate, limit, and/or terminate T-, B-, and myeloid cell activation/effector function at sites of inflammation in the periphery.
This antibody is conjugated to BD Horizon PE-CF594, which has been developed exclusively by BD Biosciences as a better alternative to PE-Texas Red. PE-CF594 excites and emits at similar wavelengths to PE-Texas Red yet exhibits improved brightness and spectral characteristics. Due to PE having maximal absorption peaks at 496nm and 564nm, PE-CF594 can be excited by the blue (488-nm), green (532-nm) and yellow-green (561-nm) lasers and can be detected with the same filter set as PE-Texas Red (eg 610/20-nm filter).
|hPD-1; PD1; PDCD1; Programmed cell death 1; SLEB2|
|Human PD-1 Recombinant Protein|
|Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.|
|Aqueous buffered solution containing BSA and ≤0.09% sodium azide|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok